PMC:7417114 / 703-855 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PD-CHEBI

    {"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T3","span":{"begin":73,"end":83},"obj":"Chemical"},{"id":"T4","span":{"begin":102,"end":111},"obj":"Chemical"}],"attributes":[{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":"g in clinical trials. Here, we characterize more than 30 approved kinase inhibitors in terms of their antiviral potential, due to their measured potency"}

    LitCovid-PD-GO-BP

    {"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T3","span":{"begin":66,"end":83},"obj":"http://purl.obolibrary.org/obo/GO_0033673"}],"text":"g in clinical trials. Here, we characterize more than 30 approved kinase inhibitors in terms of their antiviral potential, due to their measured potency"}

    LitCovid-PMC-OGER-BB

    {"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T12","span":{"begin":73,"end":83},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T1117","span":{"begin":73,"end":83},"obj":"CHEBI:35222;CHEBI:35222"}],"text":"g in clinical trials. Here, we characterize more than 30 approved kinase inhibitors in terms of their antiviral potential, due to their measured potency"}